AstraZeneca's Calquence plus chemoimmunotherapy approved for first-line treatment of mantle cell lymphoma

Alcresta Therapeutics' RELiZORB receives US FDA expanded use approval

Eli Lilly's Omvoh receives US FDA approval

Incyte and Syndax receive US FDA approval for Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vials

Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval

OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma

TNF Pharmaceuticals advances clinical trials for isomyosamine in sarcopenia and GLP-1-induced frailty

Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer

Talphera reaches FDA agreement for Prior Approval Supplement review to reduce patient numbers in Niyad study

Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval

Adaptive Biotechnologies and NeoGenomics partner to expand MRD monitoring for blood cancer

BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi

Elicera Therapeutics receives ODD for ELC-100

ReciBioPharm secures grant to expand RNA manufacturing in LMICs

Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc